Source: Healio News
Bispecific T-cell engagers have induced impressive response rates among patients with relapsed or refractory multiple myeloma enrolled in early clinical trials.
The durability of this novel immunotherapy compared with chimeric antigen receptor T-cell therapy is less certain, and longer follow-up and possible phase 2 studies are needed to provide these insights.
No bispecific T-cell engager (BTCE) has been approved for multiple myeloma in the U.S. but, if the FDA does approve one, it would be “a game changer” for clinical management of the disease, according to Nina Shah, MD,